Cenobamate as add-on therapy for drug resistant epilepsies: effectiveness, drug to drug interactions and neuropsychological impact. What have we learned from real word evidence?

• Main Authors: Nicola Pietrafusa (Author), Giovanni Falcicchio (Author), Emilio Russo (Author), Simona Lattanzi (Author), Bianca Goffredo (Author), Raffaele Simeoli (Author), Sara Cairoli (Author), Tiziana Corsetti (Author), Roberta Roberti (Author), Marina De Tommaso (Author), Federico Vigevano (Author), Angela La Neve (Author), Nicola Specchio (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Cenobamate (CNB) is an anti-seizure medication (ASM) approved in 2021 in Europe for adjunctive treatment of focal-onset seizures in adults who were not adequately controlled with at least two previous ASMs.Methods: seizure outcome, treatment-emergent adverse events, neuropsychological pr...